Last reviewed · How we verify

Tacrolimus, Accord

University of Cincinnati · FDA-approved active Small molecule Under review

Tacrolimus, Accord is a Calcineurin inhibitor Small molecule drug developed by University of Cincinnati. It is currently FDA-approved for Organ transplant rejection prophylaxis (kidney, heart, liver), Atopic dermatitis, Autoimmune conditions (off-label use in various settings). Also known as: Accord Healthcare tacrolimus.

Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription.

Tacrolimus is a small molecule inhibitor of the FK506-binding protein 1A, used in immunosuppressive regimens to prevent rejection in patients with end-stage renal failure who have undergone kidney transplantation. It is typically administered in combination with other immunosuppressants, such as mycophenolate mofetil or everolimus, as part of a reduced-dose regimen.

At a glance

Generic nameTacrolimus, Accord
Also known asAccord Healthcare tacrolimus
SponsorUniversity of Cincinnati
Drug classCalcineurin inhibitor
TargetCalcineurin (via FKBP12 binding)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). By preventing NFAT nuclear translocation, tacrolimus suppresses the transcription of IL-2 and other cytokines required for T-cell proliferation and immune response. This potent immunosuppressive effect makes it valuable in transplantation and autoimmune conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tacrolimus, Accord

What is Tacrolimus, Accord?

Tacrolimus, Accord is a Calcineurin inhibitor drug developed by University of Cincinnati, indicated for Organ transplant rejection prophylaxis (kidney, heart, liver), Atopic dermatitis, Autoimmune conditions (off-label use in various settings).

How does Tacrolimus, Accord work?

Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription.

What is Tacrolimus, Accord used for?

Tacrolimus, Accord is indicated for Organ transplant rejection prophylaxis (kidney, heart, liver), Atopic dermatitis, Autoimmune conditions (off-label use in various settings).

Who makes Tacrolimus, Accord?

Tacrolimus, Accord is developed and marketed by University of Cincinnati (see full University of Cincinnati pipeline at /company/university-of-cincinnati).

Is Tacrolimus, Accord also known as anything else?

Tacrolimus, Accord is also known as Accord Healthcare tacrolimus.

What drug class is Tacrolimus, Accord in?

Tacrolimus, Accord belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is Tacrolimus, Accord in?

Tacrolimus, Accord is FDA-approved (marketed).

What are the side effects of Tacrolimus, Accord?

Common side effects of Tacrolimus, Accord include Nephrotoxicity, Hypertension, Hyperglycemia/new-onset diabetes, Neurotoxicity (tremor, headache), Infection, Hyperkalemia.

What does Tacrolimus, Accord target?

Tacrolimus, Accord targets Calcineurin (via FKBP12 binding) and is a Calcineurin inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing